Mechanism of Action
Chemically, acetaminophen is a weak acid (pKa 9.5) capable of donating a proton. It serves as an active metabolite of phenacetin.
The primary mechanism of action involves inhibiting cyclooxygenase (COX). Unlike classic nonsteroidal anti-inflammatory drugs (NSAIDs), the drug blocks the enzyme predominantly in the central nervous system. Additionally, its analgesic effect is thought to involve modulation of the brain's serotonergic and cannabinoid systems.
Pharmacological Effects and Indications
The drug produces two prominent pharmacological effects:
- Analgesic (pain relief).
- Antipyretic (fever reduction).
Crucially: acetaminophen completely lacks anti-inflammatory activity. Its clinical efficacy in reducing fever and relieving pain is comparable to that of acetylsalicylic acid (Acidum acetylsalicylicum).
Indications:
- Reduction of fever during febrile states.
- Management of mild-to-moderate pain: headache, myalgia, neuralgia, arthralgia.
Metabolism and Biotransformation
The metabolism of Paracetamolum is a complex hepatic process involving multiple biotransformation pathways:
- Microsomal Oxidation (N-oxidation): Carried out by endoplasmic reticulum enzymes (cytochrome P450 system). The isoenzymes CYP1A2 and CYP2E1 are involved.
- CYP1A2 is influenced by diet and environment: it is induced by tobacco smoke components, charcoal-broiled foods, cruciferous vegetables, and certain drugs (omeprazole, rifampin, phenobarbital). It is inhibited by antibiotics (ciprofloxacin, macrolides) and cimetidine.
- CYP2E1 is closely linked to alcohol metabolism. It is induced by chronic ethanol (Spiritus aethylicus) intake and isoniazid. It is inhibited by disulfiram and ritonavir.
- Biosynthetic Reactions (Conjugation): The drug undergoes glucuronidation (forming glucuronic acid esters or amides) and sulfation (forming sulfates).
Toxicology and Side Effects
At therapeutic doses, the drug is safe, and side effects are rare. However, acetaminophen has a narrow therapeutic index: the toxic dose is only about 3 times the therapeutic dose.
Pathogenesis of Toxicity (Toxicification): During microsomal oxidation (primarily via CYP2E1), a reactive and highly toxic intermediate metabolite is formed: N-acetyl-p-benzoquinone imine (NAPQI). Under normal conditions, this metabolite is rapidly detoxified in the cytosol by the enzyme glutathione S-transferase via conjugation with glutathione.
In overdose or when CYP2E1 is induced (e.g., chronic alcoholism or isoniazid use), the production of this toxic metabolite surges dramatically, depleting hepatic glutathione stores. Unbound NAPQI causes severe cellular damage—hepatocyte necrosis (hepatotoxicity) and renal tubular injury.
- Antidote Therapy:
In cases of toxicity, emergency administration of sulfhydryl group donors (acetylcysteine, methionine) is required. These agents are effective only within the first 8–12 hours following ingestion, as they replenish glutathione stores to inactivate the metabolite.
Formulation and Prescribing Guidelines
The drug is administered orally.
- Formulation: 0.2 g tablets.
- Dosing Regimen: 1 to 2 tablets orally 4 times daily.
- Maximum Single Dose: 0.5 g.
- Maximum Daily Dose: 1.5 g.